Clinical Trial Update: TACE With Dicycloplatin(TP21) in Unresectable HCC [Phase 3]

View source ↗

Summary

Clinical trial update for TACE with dicycloplatin (TP21) in unresectable hepatocellular carcinoma (Phase 3) with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TACE with Dicycloplatin (TP21) (dicycloplatin)

Snippet

Sponsor: Gao-jun Teng | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN